X

Drug Profile

FP 21399

Latest Information Update: 14 Jun 2006

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EMD Lexigen; Lexigen Pharmaceuticals
Developer Lexigen Pharmaceuticals
Class Antivirals
Mechanism of Action HIV fusion inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported HIV infections

Most Recent Events

14 Jun 2006 No development reported - Phase-II for HIV infections treatment in USA (IV-infusion)
06 Oct 2000 A phase I study has been added to the adverse events, pharmacokinetics and Viral infections therapeutic use sections
22 Jun 1999 Fuji ImmunoPharmaceuticals is now called Lexigen Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com